Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.16) Estimate, Sales $1.481M Beat $1.298M Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Beats
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is unchanged from the same period last year. The company
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is unchanged from the same period last year. The company reported quarterly sales of $1.481 million which beat the analyst consensus estimate of $1.298 million by 14.11 percent. This is a 55.11 percent decrease over sales of $3.299 million the same period last year.